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ABSTRACT

EPISTASIS IN ALZHEIMER’S DISEASE: INTERACTIONS BETWEEN CLUMS4A4E AND WWC1-TLN2

Omoremi Hamblin
Department of Public Health
Bachelor of Science

Alzheimer’s disease is the most common form of dementia among people age 65
and older. Because of the complexity of this disease, many studies have taken the
epistatic approach to discovering underlying genetic disorders. Epistasis is the study of
gene-gene interaction in which the effects of one gene mask the effects of the other gene.
In this study, we attempted to replicate two earlier studies that identified three gene-gene
interactions. We used the 2019 Alzheimer’s Diseases Genetics Consortium (ADGC)
dataset and we conducted a logistic regression with and without the interaction terms.
The interactions we considered were between CLU rs11136000 and MS4A4E rs670139
(p-value = 0.537, OR = 0.97, 95% CI = 0.88,1.07), WWC1 rs3733980 and TLN2
rs7175766 in males (p-value = 0.745, OR = 0.98, 95% CI = 0.83, 1.14), and WWC1
rs1477307 and TLN2 rs4077746 in males (p-value = 0.996, OR = 0. 999, 95% CI = 0.85,
1.17). Analyses in this dataset failed to replicate any of the interactions, suggesting that
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previously-reported associations may be the result of more complex epistatic interactions,
genetic heterogeneity, or false-positive associations due to limited sample sizes.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia and it affects
more than 50 million people worldwide (Nature, 2018). It is an irreversible, degenerative
brain disorder that slowly destroys memory and thinking skills, and eventually hinders
the ability to carry out the simplest tasks (NIA, 2017). AD is characterized by the
development of beta-amyloid plaques and neurofibrillary tau tangles (Perl, 2010). It leads
to the progressive loss of connections between neurons and brain cells (Niikura, Tajima,
& Kita, 2006). There have been decades of years spent investigating AD, but there are
only very few drugs that have been shown to improve the symptoms in some patients
(NIA, 2018). However, these drugs are not very effective and certainly do not reverse the
underlying pathophysiologic processes.
There are two types of AD: Early Onset Alzheimer’s Disease (EOAD) symptoms manifest between age 30 and mid 60s - and Late Onset Alzheimer’s Disease
(LOAD) - person starts showing symptoms in their mid-60s or later. For the purposes of
this paper, we’ll be focusing on LOAD. The causes of LOAD are not yet known. It is
determined that LOAD is influenced by a combination of genetics, environmental, and
lifestyle factors (NIA, 2015). Apolipoprotein e4 (APOE e4) on chromosome 19 has been
found to be a significant risk factor for LOAD (NIH, 2015). APOE e4 is associated with
an increase in the level of amyloid deposition in the brain and is responsible for an early
age of onset of AD (DiBattista, Heinsinger, Rebeck, 2016) but not earlier than 65 years
old. The APOE e4 gene is a gene that can be inherited and passed down through
generations. An individual may have 0, 1 or 2 APOE e4 alleles. The more APOE e4
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alleles an individual has, the higher their risk of getting AD. Although APOE e4 increases
one’s risk of contracting the disease, it is not definite that a person with this gene will
have AD later in life.
Epistasis occurs when multiple genes interact to create a single phenotype
(Churchill, 2001). In some cases, gene 1 masks the effects of gene 2 making the effects of
gene 2 negligible. There are also some epistatic interactions where the genes combine to
amplify an existing trait or form a new trait (Miko, 2008). These gene-gene interactions
play a critical role in the etiology of complex diseases. Therefore, it is important to
consider the epistasis occurring in AD in order to provide a better understanding of the
complex genetic interactions that are responsible for the underlying pathophysiological
processes (Combarros, Cortina-Borja, Smith, & Lehmann, 2009).
Clusterin (CLU) is a protein encoded by the CLU gene and is found on the human
chromosome 8 (Figueroa, Gordon, Yao, & Levine, 2019). Many studies have reported its
association with AD in healthy patients (Wu, Yu, Li, Tan, 2012) (Ebbert, et al., 2016).
CLU is currently the third most associated AD risk gene in humans (Tan et al., 2016). It
has been suggested to be involved in neurodegenerative disorders and other biological
events (NCBI, 2019). Membrane spanning 4-domains A4E (MS4A4E) is a gene found on
chromosome 11 of humans (alzgene.org). The WW and C2 domain containing 1
(WWC1) encodes a WWC1 protein and is found on chromosome 5 in humans (NCBI).
Some WWC1 alleles have been suggested to be associated with enhanced memory in
some humans (NCBI, 2019). Talin 2 (TLN2) is a gene found on chromosome 15 of
humans. This gene encodes TLN2 protein which is similar to the TLN1 protein. It plays a
significant role in microfilament formation, which is important for cell shape and
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structure (NCBI, 2019). This study addresses the interactions between CLU rs11136000
and MS4A4E rs670139, WWC1 rs3733980 and TLN2 rs7175766 in males, and WWC1
rs1477307 and TLN2 rs4077746 in males.
Two previous studies (Ebbert et al., 2017; Gusareva et al., 2018) reported
evidence of three gene-gene interactions that increase AD risk. Ebbert et al. found an
interaction between rs11136000 - rs670139 (CLU-MS4A4E, p= 0.004). Guasareva et al.,
reported significant interactions between rs3733980 - rs7175766 (WWC1-TLN2, pbonferronicorrected

= 0.0165) and rs1477307 - rs4077746 (WWC1-TLN2, pbonferroni-corrected = 9.02*10-3)

in males only.
This paper expands on the previous studies and attempts to detect statistical
epistasis between CLU rs11136000 and MS4A4E rs670139, WWC1 rs3733980 and TLN2
rs7175766, and WWC1 rs1477307 and TLN2 rs4077746 with respect to AD risk using
the data from 25,772 individuals from the Alzheimer’s Disease Genetic Consortium
(ADGC).

Methods
Data Description
We used the Single Nucleotide Polymorphism (SNP) data from the ADGC dataset
which was compiled from 31 studies. This ADGC dataset was prepared on February 13,
2019 by Kevin L.Boehme, Shubhabrata Mukherjee “Joey”, and John Kauwe. The dataset
had a total of 38,876 individuals. We excluded 7000 genetically related subjects and our
analysis only considered the 31,876 unrelated individuals. Subjects were considered to be
related if they were within second cousins of each other. There were 12,501 controls
3

subjects, 13,271 cases, and 6,104 missing case-control status. Cases were those who had
been clinically diagnosed with any severity of AD. The total number of subjects in our
study was 25,772.

Dataset and Filtering
Our analysis started with genome-wide association (GWAS) data from all 31,876
individuals in the ADGC dataset as described by Naj et al. (2011). This ADGC dataset is
a collection of 31 merged datasets spanning 1984 to 2019 and was established to help
identify genetic markers of late onset AD (Boehme, Mukherjee, Crane, & Kauwe, 2014).
ADGC imputed the 31 datasets to the Haplotype Reference Consortium (HRC) reference
panel, which includes 64,976 haplotypes and 1,291,057,196 SNPs (Loh et al., 2016;
Adam C. Naj et al., 2017). Genotyped markers with a minor allele frequency less than
1% and a deviation from Hardy Weinberg Equilibrium (HWE) where ɑ<10-6 were
removed. Principal components were calculated using Eigensoft (Patterson, Price, &
Reich, 2006; Price et al., 2006) to account for population specific variations in allele
distribution. All aspects of the study was approved by institutional review boards, and
each applicant signed a written form of consent for their genetic data to be used for
research purposes.
After filtering, 13,271 cases and 12,501 control subjects contained genotypic
information for CLU rs11136000, MS4A4E rs670139, WWC1 rs3733980, WWC1
rs1477307, TLN2 rs4077746 and TLN2 rs7175766.
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Statistical Analysis
We input our data into R statistical software (R) in a .txt format. We then
converted all the missing data points into NA which is R’s format for missing data. We
did this to make sure that the missing data points were excluded from our data analyses.
We converted the AD status from a continuous variable to a categorical variable in
preparation for a logistic regression (2 = affected, 1 = unaffected). AD status was the
independent variable.
We ran a logistic regression model to determine if the interactions between the
snps of interest were associated with AD risk. We conducted a one-sided test because we
were only interested in testing if the gene interactions resulted in an increase in AD risk.
Our goal was to replicate the previous studies, so conducting a two-sided test would not
be necessary for our purposes. Our research question was “Does the interaction between
genes result in increased AD risk?” The hypotheses were Ho: gene-gene interaction does not result in increased AD risk
Ha: gene-gene interaction results in increased AD risk
We set our alpha level at 0.05. This means that if our p-value was less than 0.05, we
would reject the null hypothesis and conclude that gene-gene interaction resulted in
increased AD risk. If our p-value was greater than 0.05, we would fail to reject the null
hypothesis and conclude that the gene-gene interaction did not result in increased AD
risk.
The model of the logistic regression was
AD status = SNP1 + SNP2 + age + sex + PC1-10 + APOE4dose + (SNP1*SNP2).
where
AD status represented whether the subject had Alzheimer’s disease or not
5

SNP represented the genetic variation we tested in the participants
Age was included as a covariate to control for confounding factors
Sex was included as a covariate to control for confounding factors
PC1-10 were principal components included to ensure that the variables were not
correlated with one another. This extra measure was taken to control for genetic
similarities in the study participants’ relations that go beyond second cousins.
APOE4dose represented the dosage of APOE4 carried by the subjects. (0 - no allele, 1 - 1
allele, 2 - 2 alleles)
We included all subjects in the dataset for the first interaction analysis between CLU
rs11136000 and MS4A4E rs670139. We then stratified the dataset by gender. Only the
males were considered for the interactions between WWC1 rs3733980 and TLN2
rs7175766 and WWC1 rs1477307 and TLN2 rs4077746 because the analyses performed
by Gusareva et al. (2018) only included males.

Results
A logistic regression analysis was run for the complete dataset. We first tested the
main effects of the variants and found that MS4A4E rs670139, WWC1 rs3733980, and
TLN2 rs4077746 were each associated with AD risk (MS4A4E rs670139, p-value =
4.17e-05, OR = 1.41, 95% CI = 1.07, 1.22; WWC1 rs3733980, p-value = 0.005, OR =
0.91, 95% CI = 0.85, 0.97; TLN2 rs4077746, p-value = 1.45e-05, OR = 1.16, 95% CI =
1.08, 1.24). We observed that WWC1 rs3733980 was statistically significant for being
protective for AD. This was consistent to previous studies mentioned earlier (NCBI,
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2019). Since we are primarily interested in the epistasis between the variants, we
conducted a logistic regression analysis with each interaction term.
The first interaction between CLU rs11136000 and MS4A4E rs670139 failed to
show significant association with AD risk (p=0.54, OR = 0.97, 95% CI = 0.88, 1.07).
Since the p-value was greater than 0.05, we failed to reject the null hypothesis and
concluded that there was no statistically significant evidence for an interaction between
CLU rs11136000 and MS4A4E rs670139. The interaction between WWC1 rs3733980 and
TLN2 rs7175766 in males also failed to demonstrate significant association (p=0.75, OR
= 0.97, 95% CI = 0.83, 1.14), suggesting that the interaction between these two variants
does not result in an increased risk for AD in males. The last analysis we conducted was a
logistic regression with an interaction between WWC1 rs1477307 and TLN2 rs4077746
in males (p=.996, OR = 0.99, 95% CI = 0.85, 1.17). The insignificant p-value suggests
that there was likewise no interaction between these two variants associated with AD risk
in males.
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Table 1: Table displaying results of statistical analyses
Terms

Odds Ratio

Lower 95% CI

Upper 95% CI

P-Value

rs11136000
(CLU)

1.0002

0.9322

1.0729

0.99461

rs670139
(MS4A4E)

1.1411

1.0712

1.2153

4.17e-05 ***

rs3733980
(WWC1)

0.9095

0.8507

0.9721

0.0053 **

rs7175766
(TLN2)

1.0502

0.9808

1.1243

0.1595

rs1477307
(WWC1)

1.0539

0.9839

1.1286

0.1339

rs4077746
(TLN2)

1.1582

1.0838

1.2376

1.45e-05 ***

rs11136000*rs67 0.9700
0139

0.8807

1.0683

0.5365

rs3733980*rs717 0.9745
5766

0.8337

1.1386

0.7451

rs1477746*rs407 0.9995
7746

0.85411

1.1695

0.9955

Significance codes:
0 ‘***’

0.001 ‘**’

0.01 ‘*’

0.05 ‘.’

0.1 ‘ ’

1

Discussion
In this study, we failed to detect evidence of epistasis between the three gene-gene
interactions CLU rs11136000 and MS4A4E rs670139, WWC1 rs11136000 and TLN2
rs670139, and WWC1 rs3733980 and TLN2 rs7175766 as risk factors for AD in the
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ADGC dataset. These findings do not support the conclusions drawn in the previous
reports by Ebbert et al. (2017), and Gusareva et al. (2018). The cause for this variability
among studies could be a result of genetic heterogeneity, the complex nature of epistasis,
or false positives in the previous studies due to a limited sample size.
Although recent literature suggests that much of the unidentified genetic makeup
of AD is due to epistasis (Mez, 2016; Ebbert et al., 2014; Bullock et al., 2013), the
complex nature of gene-gene interactions makes it difficult for epistasis to be accurately
measured and defined (Urbanowicz, Kiralis, Fisher, & Moore, 2012; Gilbert-Diamond &
Moore, 2011). Models for epistatic interactions are challenging to create because such
models require large datasets to analyze combinations of variables simultaneously. When
an insufficient number of samples are used, results have poor statistical power, which can
lead to frequent false negatives in epistatic studies.
Similarly, the numerous comparisons required to assess epistasis may generate
false positive findings (Mackay & Moore, 2014). Inadequate sample size can also lead to
false positives and is identified through statistical power analyses (Christley, 2010).
Current research suggests a troubling occurence known as the “winner’s curse,” which
happens when the estimated effect of an association is inflated compared to the true
genetic effect and the effects later measured in follow-up studies (Huang, Ritchie,
Brozynska, & Inouye, 2018; Palmer & Pe’er, 2017). The level of power necessary to
accurately detect epistasis is currently unknown, and as such, replication studies are a
necessary part of validating epistasis. As our results show, studies that appear to have
sufficient power should be re-evaluated when larger datasets become available.
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Heterogeneity in the genetic causes of AD is certainly present (Mez, 2016), and
further erodes power to detect statistical epistasis. Finally, even when statistical evidence
for epistasis is detected, it does not necessarily indicate the presence of a physical
biological interaction between the implicated proteins (M.T.W. Ebbert et al., 2015).
Statistical patterns can be a product of a variety of underlying mechanisms. Therefore,
the complexity of biological and statistical epistasis could also account for disparities in
replication studies. Increasing sample sizes gives us better statistical power. Likewise,
increasing the amount of multidimensional -omics data will help us focus our efforts on
specific candidate interactions. We anticipate that as more multidimensional -omics data
become available, our ability to understand the role of epistasis in AD risk will improve
and help in the development of novel approaches to prevent and treat the disease.
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Appendix
R code used
#Read in ADGC data
ADGC <- read.table("final_adgc.txt", header = TRUE)
#Convert the -9s to
ADGC$status[ADGC$status==-9] <- NA
ADGC$apoe4dose[ADGC$apoe4dose==-9] <- NA
#Make the status variable a factor
ADGC$status <- as.factor(ADGC$status)
##Logistic Regression for entire ADGC Dataset--BINOMIAL
ADGC_Results <- glm(status~pc1 + pc2 + pc3 + pc4 + pc5 + pc6 + pc7 + pc8 + pc9 +
pc10 + apoe4dose + sex + rs670139 + rs1477307 + rs3733980 + rs4077746 + rs7175766
+ rs11136000 + age_onset, family = binomial,
data = ADGC)
summary(ADGC_Results)
#Odds ratio and confidence intervals for the full logistic regression model
require(MASS)
ci_all <- exp(cbind(coef(ADGC_Results), confint(ADGC_Results)))
summary(ci_all)

#AD status = SNP1 + SNP2 + age + sex + PC1-10 + (SNP1*SNP2)

#First interaction rs11136000, rs670139
int1 <- glm(status~pc1 + pc2 + pc3 + pc4 + pc5 + pc6 + pc7 + pc8 + pc9 + pc10 +
apoe4dose + sex + rs11136000 + rs670139 + age_onset + (rs11136000*rs670139),
family = binomial,data = ADGC)
summary(int1)
########### First Interaction CI #############
c1 <- exp(cbind(coef(int1), confint(int1)))
summary(c1)
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## Male only interactions
library(tidyverse)
ADGC_Males <- ADGC %>%
filter(sex == 1)

#Second interaction rs3733980, rs7175766 (Males Only)
int2_males <- glm(status~pc1 + pc2 + pc3 + pc4 + pc5 + pc6 + pc7 + pc8 + pc9 + pc10 +
apoe4dose + rs3733980 + rs7175766 + age_onset + (rs3733980 * rs7175766), family =
binomial, data = ADGC_Males)
summary(int2_males)
############ Second Interaction CI ##############
c2 <- exp(cbind(coef(int2_males), confint(int2_males)))
summary(c2)

#Third interaction rs1477307, rs4077746 (Males Only)
int3_males <- glm(status~pc1 + pc2 + pc3 + pc4 + pc5 + pc6 + pc7 + pc8 + pc9 + pc10 +
apoe4dose + rs1477307 + rs4077746 + age_onset + (rs1477307 * rs4077746), family =
binomial, data = ADGC_Males)
summary(int3_males)
########### Third Interaction CI ###########
c3 <- exp(cbind(coef(int3_males), confint(int3_males)))
summary(c3)
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